Fairvalue-Calculator Fairvalue-Calculator
EN DE

Celyad Oncology SA (CYAD) Fair Value & Analysis

Healthcare · BE · Market cap €11.7M

Price€0.2450
Fair Value€0.4100
Upside+67.3%
Quality95/100
Evidence: Medium Range €0.3100 – €1.12

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Celyad Oncology SA (CYAD) currently trades at €0.2450, while our model-based Fair Value estimate is €0.4100 — implying the stock looks roughly 67.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Celyad Oncology SA (CYAD) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.4100 versus a price of €0.2450 — about +67% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CYAD?
Our 21-model fair value for Celyad Oncology SA is €0.4100 (as of Jun 24, 2026), built from audited fundamentals. The current price is €0.2450.
What is the quality score of CYAD?
Celyad Oncology SA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.